Cargando…

Therapeutic novelties in migraine: new drugs, new hope?

BACKGROUND: In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies. MAIN BODY: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Do, Thien Phu, Guo, Song, Ashina, Messoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734360/ https://www.ncbi.nlm.nih.gov/pubmed/30995909 http://dx.doi.org/10.1186/s10194-019-0974-3

Ejemplares similares

Correction to: Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
por: Do, Thien Phu, et al.
Publicado: (2023)

The K(ATP) channel in migraine pathophysiology: a novel therapeutic target for migraine
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2017)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

Cluster headache – The worst possible pain on YouTube
por: Chaudhry, Basit Ali, et al.
Publicado: (2022)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
por: Cullum, Christopher Kjaer, et al.
Publicado: (2022)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey
por: Do, Thien Phu, et al.
Publicado: (2022)

Characterizing healthcare utilization patterns in a Danish population with headache: results from the nationwide headache in Denmark (HINDER) panel
por: Do, Thien Phu, et al.
Publicado: (2023)

The chronobiology of migraine: a systematic review
por: Poulsen, Amanda Holmen, et al.
Publicado: (2021)

Brain barriers and their potential role in migraine pathophysiology
por: Wiggers, Astrid, et al.
Publicado: (2022)

Imaging the inflammatory phenotype in migraine
por: Christensen, Rune Häckert, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis
por: Christensen, Casper Emil, et al.
Publicado: (2022)

Barriers and gaps in headache education: a national cross-sectional survey of neurology residents in Denmark
por: Do, Thien Phu, et al.
Publicado: (2022)

Migraine aura‐like episodes following sclerotherapy for varicose veins of the lower extremities—A systematic review
por: Bahtiri, Lionesa, et al.
Publicado: (2023)

The role of high‐conductance calcium‐activated potassium channel in headache and migraine pathophysiology
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2022)

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial
por: Falkenberg, Katrine, et al.
Publicado: (2018)

Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies
por: Thuraiaiyah, Janu, et al.
Publicado: (2022)

Migraine attacks are of peripheral origin: the debate goes on
por: Do, Thien Phu, et al.
Publicado: (2023)

Migraine and cluster headache – the common link
por: Vollesen, Anne Luise, et al.
Publicado: (2018)

New drugs for migraine
por: Stovner, Lars Jacob, et al.
Publicado: (2009)

Clinical features of visual migraine aura: a systematic review
por: Viana, Michele, et al.
Publicado: (2019)

Debate: Are cluster headache and migraine distinct headache disorders?
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2022)

Myofascial trigger points in migraine and tension-type headache
por: Do, Thien Phu, et al.
Publicado: (2018)

Locating Organizations and Their Methods in Registrations of Clinical Migraine Trials: Analysis of ClinicalTrials.gov
por: Zhang, Pengfei, et al.
Publicado: (2021)

New Oral Drugs for Migraine
por: Karsan, Nazia, et al.
Publicado: (2022)

PACAP38 in human models of primary headaches
por: Ashina, Håkan, et al.
Publicado: (2017)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
por: Guo, Song, et al.
Publicado: (2022)

Therapeutical Novelties
Publicado: (1854)

Correction: PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
por: Guo, Song, et al.
Publicado: (2023)

Migraine and risk of hemorrhagic stroke: a study based on data from general practice
por: Gaist, David, et al.
Publicado: (2014)

The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics
por: Karlsson, William Kristian, et al.
Publicado: (2023)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope
por: Nabi, Showkat Ul, et al.
Publicado: (2022)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cp5mrb5v2ip49e5q3151scufhj